Pharsight

Seysara is owned by Almirall.

Seysara contains Sarecycline Hydrochloride.

Seysara has a total of 4 drug patents out of which 0 drug patents have expired.

Seysara was authorised for market use on 01 October, 2018.

Seysara is available in tablet;oral dosage forms.

Seysara can be used as a method for treating a bacterial infection in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride, a method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering sarecycline hydrochloride in 60 mg, 100 mg or 150 mg equivalent doses, a method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride crystalline salt; a method for treating a bacterial infection in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride crystalline salt, a method for treating a patient 9 years of age and older suffering from an inflammatory skin disorder of non-nodular moderate to severe acne vulgaris comprising administering an effective amount of sarecycline hydrochloride.

Drug patent challenges can be filed against Seysara from October, 2022.

The generics of Seysara are possible to be released after 09 February, 2033.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8318706	ALMIRALL	Substituted tetracycline compounds	May, 2031 (8 years from now)
US9255068	ALMIRALL	Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same	Feb, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9481639	ALMIRALL	Substituted tetracycline compounds for treatment of inflammatory skin disorders	Aug, 2028 (5 years from now)
US8513223	ALMIRALL	Substituted tetracycline compounds for treatment of inflammatory skin disorders	Dec, 2029 (6 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Oct 1, 2023

Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient

NCE-1 date: October, 2022

Market Authorisation Date: 01 October, 2018

Treatment: A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering sarecycline hydrochloride in 60 mg, 100 mg or 150 mg equivalent doses; A method for treating a patient 9 years of age and older suffering from an inflammatory skin disorder of non-nodular moderate to severe acne vulgaris comprising administering an effective amount of sarecycline hydrochloride; A method for treating a bacterial infection in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride; A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride crystalline salt; A method for treating a bacterial infection in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride crystalline salt

Dosage: TABLET;ORAL